Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at HC Wainwright upped their FY2024 earnings per share estimates for Xeris Biopharma in a research note issued to investors on Monday, November 11th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.41) per share for the year, up from their previous forecast of ($0.42). HC Wainwright currently has a "Buy" rating and a $6.60 price target on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma's Q4 2024 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.03) EPS and FY2028 earnings at $0.51 EPS.
Separately, Piper Sandler cut shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a research report on Monday.
Get Our Latest Report on Xeris Biopharma
Xeris Biopharma Stock Performance
Shares of XERS stock remained flat at $3.15 during mid-day trading on Wednesday. 1,864,403 shares of the stock were exchanged, compared to its average volume of 1,730,846. The firm's 50 day simple moving average is $2.98 and its 200-day simple moving average is $2.52. Xeris Biopharma has a 1 year low of $1.46 and a 1 year high of $3.64.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Simplicity Wealth LLC purchased a new stake in shares of Xeris Biopharma in the second quarter worth $27,000. Wealth Enhancement Advisory Services LLC bought a new position in Xeris Biopharma in the 3rd quarter worth about $35,000. Bayesian Capital Management LP purchased a new stake in Xeris Biopharma during the 1st quarter valued at about $37,000. Allspring Global Investments Holdings LLC increased its stake in Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company's stock valued at $37,000 after purchasing an additional 15,929 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Xeris Biopharma in the third quarter worth about $44,000. Hedge funds and other institutional investors own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Articles
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
